Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

OTHER 7INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Keratosis, Actinic 18Keratosis 3Condylomata Acuminata 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Glioblastoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Sialorrhea 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma 1

Interventions

HhAntag691 11sonidegib 5cemiplimab 5methyl 5-aminolevulinate 4daromun 4Imiquimod 3IPI-926 3gusacitinib 2Photochemotherapy 2Drug Evaluation 23-ingenyl angelate 2tozuleristide 1silmitasertib 1pembrolizumab 1TAK-441 1NVP-LEQ506 1MAPRE1 protein, human 1Intravital Microscopy 1Interleukin-2 1Injections 1IFL protocol 1Folfox protocol 1Capecitabine 1Bevacizumab 1BO-112 1BMS-833923 1BF-200 ALA 1Ascorbic Acid 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Basal Cell × Imiquimod × Clear all
NCT00189280 2022-02-22

Aldara for the Treatment of Large and/or Multiple sBCC

Viatris Inc.

Phase 3 Completed
111 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00189241 2022-02-07

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Viatris Inc.

Phase 3 Completed
160 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00129519 2010-07-16

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

Graceway Pharmaceuticals, LLC

Phase 3 Completed
63 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡